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Genome-wide association analyses of physical
activity and sedentary behavior provide insights
into underlying mechanisms and roles in disease
prevention
Although physical activity and sedentary behavior are moderately heritable, little is known about the mechanisms that
influence these traits. Combining data for up to 703,901 individuals from 51 studies in a multi-ancestry meta-analysis of
genome-wide association studies yields 99 loci that associate with self-reported moderate-to-vigorous intensity physical
activity during leisure time (MVPA), leisure screen time (LST) and/or sedentary behavior at work. Loci associated with LST
are enriched for genes whose expression in skeletal muscle is altered by resistance training. A missense variant in ACTN3
makes the alpha-actinin-3 filaments more flexible, resulting in lower maximal force in isolated type IIA muscle fibers, and
possibly protection from exercise-induced muscle damage. Finally, Mendelian randomization analyses show that beneficial
effects of lower LST and higher MVPA on several risk factors and diseases are mediated or confounded by body mass index
(BMI). Our results provide insights into physical activity mechanisms and its role in disease prevention.

L

ow levels of physical activity have a major effect on disease
burden and it is estimated that more than 5 million deaths per
year might be prevented by ensuring adequate levels1. Despite
efforts to increase physical activity levels2, an estimated 28% of the
world's population is insufficiently active, and the prevalence of
physical inactivity in high-income countries rose from 31.6% in
2001 to 36.8% in 2016 (ref. 3). Trends of decreasing physical activity
levels over time coincide with increases in the time spent sedentary4, which may pose an independent risk for public health5,6.
Physical activity and sedentary behavior are affected by public
policy and social support, as well as by cultural, environmental
and individual factors7. Factors like socioeconomic status, built
environment and media all influence physical activity at a population level7. In parallel, innate biological factors (for example,
age, sex hormones, pre-existing medical conditions, epigenetics
and genetics) also explain a moderate proportion of the interindividual variability in physical activity and sedentary behavior.
Heritability estimates (h2) range from 31% to 71% in large twin
studies8,9. Identifying the genetic factors that influence daily
physical activity will improve our understanding of this complex
behavior, and may (1) facilitate unbiased causal inference; (2)
help identify vulnerable subpopulations; and (3) fuel the design
of tailored interventions to effectively promote physical activity.
A mechanistic understanding of physical activity at a molecular
level may even allow its beneficial effects to be attained through
pharmacological intervention10.
Genome-wide association studies (GWAS) have identified
thousands of loci associated with cardiometabolic risk factors and
diseases11. However, similar efforts for physical activity have been
sparse and initially had limited success. This likely reflects the comparatively small sample size of these efforts12, along with heterogeneous assessments of physical activity across studies. More recently,
GWAS using data from UK Biobank identified nine loci associated
with self-reported moderate and/or vigorous intensity physical
activity or sports and exercise participation (n ≈ 377,000 individuals) and eight associated with accelerometry-assessed physical

activity and sedentary behavior (n ≈ 91,000)13,14. Hence, on the
assumption that physical activity is a highly polygenic trait, many
common variants influencing physical activity undoubtedly remain
to be identified.
Here, we combine data from up to 703,901 individuals (94.0%
European, 2.1% African, 0.8% East Asian, 1.3% South Asian ancestries, and 1.9% Hispanic) from 51 studies in a multi-ancestry
meta-analysis of GWAS for MVPA, LST, sedentary commuting and
sedentary behavior at work. This yields 104 independent association signals in 99 loci, implicating brain and muscle, among others organs. Follow-up analyses improve our understanding of the
molecular basis of leisure time physical activity and sedentary
behavior, and their role in disease prevention.

Results

Genome-wide analyses yield 99 associated loci. In our primary
meta-analysis of European ancestry men and women combined
(Supplementary Tables 1, 2), we identify 91 loci that are associated (P < 5 × 10−9) with at least one of four self-reported traits:
MVPA (n up to 606,820), LST (n up to 526,725), sedentary commuting (n up to 159,606) and sedentary behavior at work (n up to
372,605) (Supplementary Table 3, Figs. 1 and 2, and Supplementary
Fig. 1). The non-European ancestry meta-analyses do not provide
new associations themselves and are only used in multi-ancestry
meta-analyses. Multi-ancestry and sex-specific meta-analyses
yield eight additional loci, resulting in a total of 104 independent
association signals in 99 loci (Supplementary Tables 3 and 4). The
vast majority of these—89 independent single nucleotide polymorphisms (SNPs) in 88 loci (35 not previously reported13,15)—are
associated with LST, explaining 2.75% of its variance. We also identify 11 loci for MVPA (six not previously reported13,15,16, four that
overlap with LST) and four loci for sedentary behavior at work (all
previously reported13,15; Supplementary Table 3). No loci are identified for sedentary commuting. To increase statistical power for the
discovery of new loci, we perform a multi-trait analysis of GWAS
(MTAG) using summary statistics of MVPA and LST. This yields
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Fig. 1 | Overview of the four self-reported physical activity and sedentary traits and correlations with objectively assessed traits. a, An overview of
the four self-reported physical activity and sedentary traits. b, Phenotypic (upper left) and genetic (lower right) correlation coefficients between the four
self-reported physical activity and sedentary traits studied here and three accelerometer-assessed traits quantified in UK Biobank participants. AccMod,
accelerometer-assessed proportion of time spent in moderate intensity physical activity; AccSed, accelerometer-assessed proportion of time spent
sedentary; AccWalking, accelerometer-assessed proportion of time spent walking; SDC, sedentary commuting behavior; SDW, sedentary behavior at work.

13 additional loci: eight loci for MVPA and eight for LST, with three
loci overlapping (Supplementary Table 5)17.
SNP-heritability estimates range from 8% for MVPA to 16% for
LST (Supplementary Table 6 and Methods). Genetic correlations
between the four traits range from −0.32 for sedentary behavior
at work and sedentary commuting, to −0.49 for LST and MVPA
(Fig. 1b). To ensure adequate statistical power in instrumental variable and enrichment analyses, we focus on LST and MVPA from
here onwards.
Genetic correlations of self-reported LST and MVPA with
objective, accelerometry-assessed daily physical activity traits in
UK Biobank range from 0.14 to 0.44 (Fig. 1b). Importantly, five
of the eight loci previously identified for objectively assessed daily
physical activity in UK Biobank data13,14 show directionally consistent associations (P < 0.05) with self-reported LST and/or MVPA
in our study (Supplementary Table 7). By contrast, 39 LST- and 4
MVPA-associated loci observed here show directionally consistent associations (P < 0.05) with at least one objectively assessed
physical activity and/or sedentary trait (using accelerometry) in UK
Biobank (Supplementary Table 8). In line with this, each additional
LST-decreasing and MVPA-increasing allele in unweighted genetic
predisposition scores of the 88 LST- and 11 MVPA-associated
loci, respectively, are associated with higher objectively assessed
daily physical activity levels in UK Biobank (P = 5 × 10−23 for LST;
P = 2 × 10−3 for MVPA, Supplementary Table 8).
As external validation, we use the European ancestry summary statistics of LST and MVPA to construct polygenic scores
(PGSs), and examine their associations with MVPA in 8,195 BioMe
BioBank participants of European (n = 2,765), African (n = 2,224)
and Hispanic (n = 3,206) ancestry. In general, a higher PGS for
MVPA is associated with higher odds of engaging in more than 30
min per week of MVPA, and a higher PGS for LST with lower odds
of engaging in MVPA. Individuals at the highest decile of the PGS

for LST are 26% less likely to spend more than 30 min per week
on MVPA compared with individuals at deciles 4 to 6 (odds ratio
(OR) [95% confidence intervals (CI)] = 0.74 [0.55–0.99]) (Fig. 3
and Supplementary Table 9).
Shared genetic architecture. Using linkage disequilibrium (LD)
score regression implemented in the LD-Hub18, we observe significant (P < 4.6 × 10−4) genetic correlations of LST and MVPA with
adiposity-related traits (r = −0.41 to −0.20), especially with body
fat percentage (rg = 0.4 and −0.3, respectively; Fig. 4, Supplementary
Fig. 2 and Supplementary Table 10). In line with moderate genetic correlations, 11 of the 99 self-reported loci for physical activity and sedentary behavior have previously been associated with obesity-related
traits19–25. In addition, PGSs for lower LST and higher MVPA are
associated with lower BMI in up to 23,723 participants from the
BioMe BioBank (Supplementary Table 9), and a phenome-wide association study (PheWAS) in 8,959 BioMe European ancestry samples
shows a negative association between the PGS for MVPA and morbid obesity (P = 1.1 × 10−5, Supplementary Fig. 3). Strikingly, genetic
correlations with body fat percentage are similar for self-reported
LST, MVPA (Fig. 4) and accelerometer-assessed physical activity
traits13,14 (Supplementary Fig. 2).
Besides adiposity, less sedentary behavior and higher physical
activity levels are also genetically correlated with a more favorable
cardiometabolic status, including lower triglyceride, total cholesterol, fasting glucose and fasting insulin levels, and lower odds of
type 2 diabetes and coronary artery disease; as well as with better
mental health outcomes, a lower risk of lung cancer and with longevity (Fig. 4 and Supplementary Fig. 2).
Causal inference. To assess directions of causality between sedentary behavior/physical activity and BMI, we next perform twosample Mendelian randomization (MR) analyses using multiple
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Fig. 2 | Main results of GWAS and downstream gene prioritization for LST and MVPA. a, Circular Manhattan plot summarizing the results from European
ancestry meta-analyses for LST and MVPA. Outer track, LST; inner track, MVPA. Genome-wide significant variants (P < 5 × 10−9) are highlighted in orange
for loci associated with MVPA and in blue for loci associated with LST. b, Dendrogram showing the 101 independent association signals in LST- and
MVPA-associated loci from European ancestry or multi-ancestry meta-analyses. Moving outwards from the center are: (1) chromosome; (2) lead SNP
identifiers, in orange for loci associated with MVPA, in blue for loci associated with LST; (3) the most promising gene(s) prioritized in the locus (closest
genes are highlighted by filled circles); and (4) the approach(es) by which the gene was prioritized, that is, DEPICT gene prioritization (Dg) or tissue
enrichment (Dt); SMR of eQTL signals in blood (Sbl), brain (Sbr) or skeletal muscle (Ssm); credible variants identified by FINEMAP that (i) are coding and
likely to have a detrimental effect on protein function (Fcadd) or (ii) show evidence of three-dimensional interactions with the candidate gene in central
nervous system cell types (Fcrt); activity-by-contact (ABC) in 26 relevant tissues and cell types; a contribution to enrichment for altered expression in
skeletal muscle following a resistance training intervention (RTsm); and/or proximity to an association signal for spontaneous running speed (Ms), time
run (Mt) or distance run (Md) in a GWAS of 100 inbred mouse strains.

MR methods that utilize genome-wide full summary results
or genome-wide significant loci (Supplementary Table 11 and
Methods)26–30. Causal Analysis Using Summary Effect Estimates
(CAUSE)26 as well as traditional MR methods consistently show that
LST and BMI causally affect each other, with the causal effect (the
per 1 s.d. unit increase in each trait) of higher LST on higher BMI
being two- to threefold larger than the effect of BMI on LST (Fig. 5a,
Table 1 and Supplementary Table 11). Results are similar for bidirectional causal inference tests using body fat percentage instead of
BMI (Table 2). However, CAUSE cannot distinguish a model of causality from horizontal pleiotropy for body fat percentage and LST
(Table 2). CAUSE also illustrates a causal effect of higher LST on
higher recalled adiposity and height in childhood (Table 2), supporting our hypothesis that a genetic predisposition for higher LST
later in life represents a lifelong predisposition that already influences adiposity through sedentary behavior early in life. We observe
similar evidence for causal effects between MVPA and adiposity,
with smaller effects when compared with LST.
We next investigate the causal effects of LST and MVPA on
common diseases and risk factors, with and without adjusting for
BMI (Supplementary Tables 12 and 13). In univariate analyses, we
observe effects of lower LST on higher high-density lipoprotein
cholesterol levels, higher parental age at death, and on lower odds of
type 2 diabetes, attention deficit hyperactivity disorder and depression. The CAUSE model only supports evidence for a causal effect
of LST on attention deficit hyperactivity disorder and parental age at
1334

death. Importantly, multivariable MR analyses show that all protective causal effects of lower LST are either mediated or confounded
by BMI.
Directions of causal effects are consistent across LST and MVPA,
but only reach significance for MVPA on parental age at death when
using the CAUSE model. As for LST, multivariable MR results suggest that the protective causal effects of higher MVPA are either
mediated or confounded by BMI, but results should be interpreted
with caution for MVPA because of weak instrument bias (conditional F statistics <10)31 (Fig. 5b and Supplementary Table 13).
Gene expression in skeletal muscle following training. Although
behavior is mainly influenced by signals from the brain, in the case
of physical activity, characteristics of skeletal muscle can play a
facilitating or restricting role32. Therefore, we next examine whether
genes in LST- and MVPA-associated loci are enriched for altered
messenger RNA expression in skeletal muscle following an acute
bout of exercise or a period of training or inactivity33 (Methods).
A mild enrichment for transcripts with an altered expression in
skeletal muscle after resistance training is observed for genes nearest to lead SNPs in LST-associated loci (P = 0.02) (Extended Data
Figs. 1 and 2, and Supplementary Table 14). Of the ten genes driving the enrichment, PDE10A may play a critical role in regulating
cyclic AMP and cyclic GMP levels in the striatum, a brain region
that harbors the central reward system and is important for physical
activity regulation34, and in regulating striatum output35; ILF3 and
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Table 1 | Bidirectional MR results for LST and MVPA with BMI or body fat percentage using significant loci only
Exposure

Outcome

Beta

s.e.

P value

Exposure

Outcome

Beta

s.e.

P value

LST

Body fat %

0.16

0.07

0.016

LST

BMI

0.40

0.04

8.4 × 10−14

Body fat %

LST

0.12

0.03

0.005

BMI

LST

0.16

0.01

1.4 × 10−74

MVPA

Body fat %

−0.21

0.17

0.22

MVPA

BMI

−0.25

0.04

0.002

Body fat %

MVPA

−0.001

0.036

0.97

BMI

MVPA

−0.10

0.01

5.8 × 10−12

We use MR-PRESSO with outliers removed for all pairs of traits except for the causal effect estimation between body fat percentage (body fat %) and MVPA because no outliers were detected by
MR-PRESSO. For body fat percentage → MVPA, we reported the causal estimates using an inverse variance-weighted test; for MVPA → body fat percentage, we reported the weighted median method
because these two methods were selected by the machine learning framework (Methods) to be the most appropriate approaches for each analysis, respectively. P < 0.0125 indicates significant effects.

NECTIN2—near APOE—influence the host response to viral infections36,37; EXOC4 plays a role in insulin-stimulated glucose uptake in
skeletal muscle38; and IMMP2L influences the transport of proteins
across the inner mitochondrial membrane39 (Supplementary Note).
Visual information processing and the reward system. To further improve the understanding of the biological factors that influence sedentary behavior and physical activity, we perform a tissue
enrichment analysis using DEPICT40. LST- and MVPA-associated
loci (P < 1 × 10−5) are most significantly enriched for genes
expressed in the retina, visual cortex, occipital lobe and cerebral
cortex. This suggests that: (1) possibly subtle differences in the ability to receive, integrate and process visual information influence
the likelihood to engage in MVPA; (2) MVPA alters the expression
of genes that play a role in visual processes in these tissues; and/or
(3) MVPA can slow age-related perceptual and cognitive decline41.
The LST-associated loci yield similar tissue enrichment results,
with retina having the lowest P value for enrichment. Interestingly,
enrichment for genes expressed in retina was also observed in the
High Runner mouse model42. Areas related to the reward system
(for example, the hippocampus and limbic system) and to memory
and navigation (for example, the entorhinal cortex, parahippocampal gyrus, temporal lobe and limbic system) are also enriched in
both LST- and MVPA-associated loci (Extended Data Fig. 3 and
Supplementary Table 15).
We next use CELLECT43 to identify enriched cell types using
single-cell RNA sequencing data from the Tabula Muris and mouse
brain projects44. In Tabula Muris data, we observe enrichment in
nonmyeloid neurons for MVPA and LST, and of nonmyeloid oligodendrocyte precursor cells for MVPA, possibly highlighting a role
for signal transduction (Extended Data Fig. 4 and Supplementary
Table 16). In mouse brain data, we identify enrichment for 13 and
45 cell types from 3 and 12 distinct brain regions for MVPA and
LST, respectively, including enrichment in dopaminergic neurons
(Extended Data Fig. 4 and Supplementary Table 16); a key feature of
physical activity regulation in mice45.
Candidate gene prioritization. To explore mechanisms by which
the identified loci may influence LST and MVPA, we next pinpoint
genes in GWAS-identified loci: (1) contributing to tissue enrichment or identified by DEPICT’s gene prioritization algorithm
(Supplementary Tables 15 and 17); (2) whose expression in brain,
blood and/or skeletal muscle is anticipated to mediate the association
between locus and outcome based on Summary-based MR46 (SMR;
Supplementary Table 18); (3) harboring credible variants with a
high posterior probability of being causal (>0.80)47 and a predicted
deleterious effect on protein function (Supplementary Table 19)48;
(4) showing chromatin–chromatin interactions with credible variants in central nervous system cell types (such genes may be further from lead SNPs, Supplementary Table 19); (5) that—across
26 tissues and cell types—are activated by contact with enhancers presumably affected by causal variants flagged by GWAS hits49

(Supplementary Tables 20–22); (6) associated with physical activity
in GWAS in humans and mice and located <100 kb from the lead
variant in humans or mice (Supplementary Note, Supplementary
Fig. 4 and Supplementary Tables 23 and 24); and (7) driving enrichment of altered expression in skeletal muscle following resistance
exercise training (Supplementary Table 14). Twelve (14%) of the
LST-associated loci harbor a variant with a high (>80%) posterior probability of being causal, whereas such variants were not
identified among the 11 MVPA-associated loci (Supplementary
Table 19). Integrating results across approaches yields 268 candidate genes in 70 LST-associated loci and 39 candidate genes in 8
MVPA-associated loci. Forty-six candidate genes are prioritized
by multiple approaches (42 for LST and 6 for MVPA; 2 overlap)
and point to endocytosis (CNIH2, RAB1B, KLC2, PACS1, REPS1,
DNM3, EXOC4), locomotion (CADM2, KLC2) and myopathy
(MLF2, HERC1, KLC2, SIL1) as relevant pathways (Supplementary
Tables 25 and 26, and Supplementary Note). Seven clusters of protein–protein interactions are predicted, involving 17 of the 46 genes
(Extended Data Fig. 5). In vivo perturbation in model systems is
required to confirm or refute a role in sedentary behavior and physical activity.
Enrichment of previously reported candidate genes. Candidate
gene studies in humans have aimed to identify and characterize
the role of genes in exercise (physical activity behavior) and fitness
(physical activity ability) for decades. We next examine whether
variants in genes that have been linked to or associated with exercise
and fitness show evidence of associations with self-reported LST and
MVPA12,50–54. Of the 58 previously described candidate genes (13 for
exercise; 45 for fitness), 56 (13 for exercise and 43 for fitness) harbor variants with P < 0.05 for associations with LST and/or MVPA
(Pbinomial = 2.1 × 10−70; Supplementary Fig. 5 and Supplementary
Table 27). Associations reach traditional genome-wide significance
(P < 5 × 10−8) for variants in three genes: APOE55, PPARD56 and
ACTN3 (ref. 57) (Methods).
The SNP in APOE with the lowest P value for association with
LST is rs429358, for which the C allele associated with lower LST
was previously associated with higher self-reported MVPA13 and
forms part of the Ɛ4 risk allele for Alzheimer’s disease (Discussion).
The SNP with the lowest P value for association with LST in the
locus is rs6857 (D′ = 0.90; r2 = 0.78 with rs429358), in the 3′ untranslated region of NECTIN2. Neither rs429358 (P = 0.16) nor rs6857
(P = 0.18) is associated with MVPA in this study.
The C allele in rs1625595, ~300 kb upstream of ACTN3, is associated with higher MVPA (P = 1.9 × 10−11) as well as with higher
ACTN3 expression in skeletal muscle (GTEx, P = 6.6 × 10−5).
Alpha-actinin-3 (ACTN3) forms a structural component of the
muscle’s Z-disc that is exclusively expressed in type IIA and IIX
muscle fibers58. rs1815739, a common ACTN3 variant that introduces a premature stop codon, p.Arg577Ter, also known as
p.Arg620Ter, has been extensively studied in the context of exercise performance57. Although we observe little evidence for a role
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Fig. 3 | Validation of associations with MVPA and LST using PGSs in BioMe participants of three ancestries. a,c, The best performing PGSs for MVPA
(a) and LST (c) were derived using logistic/linear regression analyses; that is, those with the highest incremental R2 above and beyond models with only
sex, age and the top ten principal components. This was accomplished using inclusion thresholds of P < 0.1101 for MVPA and P < 0.14 for LST. b,d, The
association—examined using a logistic regression analysis—of MVPA with the PGSs for MVPA (b) and LST (d) in individuals of African (AA, n = 2,224),
European (EA, n = 2,765) and Hispanic (HA, n = 3,206) ancestry in data from the BioMe BioBank. Dots and error bars show OR and 95% CI.

of rs1815739 in leisure time sedentary behavior or physical activity
(PLST = 0.017, PMVPA = 0.17), the intronic ACTN3 variants rs679228
(PLST = 4.3 × 10−8) and rs2275998 (PMVPA = 1.8 × 10−7) do show evidence of such associations. Of these, rs2275998—located 646 bp
downstream of p.Arg577Ter—is in full LD (r2 = 1.0) with the missense variant rs2229456 (p.Glu635Ala), which likely affects protein
function (Combined Annotation Dependent Deletion (CADD)
score for the derived, minor, p.635Ala variant =28.6). Each C
allele in rs2229456 is associated with less LST (P = 1.4 × 10−4) and
higher odds of engaging in MVPA (P = 8.3 × 10−7). Of note, given
its downstream location from p.Arg577Ter, a potentially causal
effect of rs2229456 on physical activity requires absence of the
protein-truncating p.Arg577Ter variant in rs1815739. Haplotype
analyses support this (Supplementary Table 28).
Greater ACTN3 flexibility with p.635Ala. Given the striking
finding that MVPA and LST are associated with the ACTN3 missense variant rs2229456, but not with the ACTN3-truncating variant rs1815739, we next examine whether rs2229456 (p.Glu635Ala
1336

variant) has functional consequences for ACTN3’s mechanistic
properties at the molecular level. We add ACTN2 to this comparison because it likely compensates for the loss of ACTN3 in the
presence of the truncating p.Arg577Ter variant59. The results of
computer-based (steered) molecular dynamics (MD) simulations
and umbrella sampling (see Methods and Supplementary Note for
more details) show that the ancestral p.Glu635 variant facilitates
salt-bridge and hydrogen-bonding interactions at residue 635 with
surrounding residues (for example, R638 and Q639; Fig. 6a,b and
Supplementary Fig. 6) via its glutamate side chain. Such interactions are not formed in the presence of the ACTN3 p.635Ala product. They are also less likely to be formed in ACTN2, because of a
kink that is present at exactly this location in ACTN2 (Fig. 6c and
Supplementary Fig. 6). Moreover, p.635Ala and ACTN2 show distinctly different behavior from p.Glu635, with a greater magnitude
of root mean squared fluctuations (r.m.s.f.) in the middle section
of the spectrin repeats under no-load conditions (Fig. 6d), suggesting a more flexible structural region. When placed under simulated
compressive loads that are likely experienced in vivo, p.635Ala
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shows a more linear force versus distance relationship, with greater
variance in the potential of mean force (Fig. 6e and Supplementary
Fig. 6). Taken together, these results indicate that the ACTN3
p.635Ala dimer—associated with higher MVPA—exhibits similar
flexibility to ACTN2 and greater flexibility than the p.Glu635 dimer.
Maximal force and fiber power lower with ACTN3 p.635Ala. We
next examine whether a higher predicted ACTN3 dimer flexibility
in the presence of p.635Ala has functional consequences in isolated
human skeletal muscle fibers. To this end, we compare functional
readouts in 298 isolated type I and IIA fibers from vastus lateralis
biopsies obtained from eight healthy, young, untrained male participants before and after an eccentric exercise bout60,61. Results from a
15,000 iteration Markov chain Monte Carlo model show that stable
maximal force—with fibers submerged in activating solution—and
fiber power during isotonic load clamps are similar in 32 ± 7 fibers
(mean ± s.d.) from three p.Arg577 homozygous, p.Glu635Ala heterozygous individuals compared with 39 ± 6 fibers from four individuals homozygous for the p.577Ter variant; and lower in both

groups when compared with 46 fibers from an individual that is
homozygous for both the p.Arg577 and p.Glu635 variants (Fig. 6f
and Methods). Associations are most striking after an eccentric
exercise intervention and are, as expected, more pronounced in
type IIA than in type I fibers (Supplementary Fig. 7). Taken together,
these results suggest that a more flexible ACTN dimer with lower
peak performance (ACTN3 p.635Ala or ACTN2) may be less susceptible to exercise-induced muscle damage than the ancestral
ACTN3 p.Glu635, thereby facilitating a more active lifestyle.

Discussion

By doubling the sample size compared with earlier GWAS, we
identify 104 independent association signals in 99 loci, including
42 newly identified loci, for self-reported traits reflecting MVPA
and sedentary behavior during leisure time. Around half of these
also show evidence of directionally consistent associations with
objectively assessed physical activity traits. Genetic correlations
and two-sample MR analyses show that lower LST results in lower
adiposity. Protective causal effects of higher MVPA and lower
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Table 2 | Bidirectional MR results for LST and MVPA during leisure time with BMI or body fat percentage using genome-wide
summary results (CAUSE method)
Exposure

Outcome

Gammaa

95% CI

P valueb

Exposure

Outcome

Gammaa

95% CI

P valueb

LST

Body fat %

0.18

0.13 to 0.24

1.8 × 10

LST

BMI

0.31

0.28 to 0.35

6.7 × 10−28

Body fat %

LST

0.12

0.04 to 0.18

0.14

BMI

LST

0.18

0.16 to 0.19

1.1 × 10−14

MVPA

Body fat %

−0.12

−0.20 to −0.04

0.07

MVPA

BMI

−0.14

−0.20 to −0.07

6.0 x 10−3

Body fat %

MVPA

−0.03

−0.09 to 0.02

0.53

BMI

MVPA

−0.09

−0.11 to −0.06

7.4 x 10−3

LST

Comparative height at age 10

0.03

0.01 to 0.04

0.04

LST

Comparative body 0.02
size at age 10

0.01 to 0.03

0.04

−3

a
Posterior median of gamma, which can be taken as a point estimate of the causal effect. This estimate tends to be shrunk slightly toward zero compared with other methods. bThe P value for comparing the
causal model with the sharing model. P < 0.05 indicates that posteriors estimated under the causal model predict the data significantly better than posteriors estimated under the sharing model.

LST—acting through or confounded by BMI—are observed for longevity. Tissue and cell-type enrichment analyses suggest a role for
visual information processing and the reward system in MVPA and
LST, including enrichment for dopaminergic neurons. Loci associated with LST are enriched for genes whose expression in skeletal
muscle is altered by resistance training. Forty-six candidate genes
are prioritized by more than one approach and point to pathways
related to endocytosis, locomotion and myopathy. Finally, results
from MD simulations, umbrella sampling and single fiber experiments suggest that a missense variant (rs2229456 encoding ACTN3
p.Glu635Ala) likely increases MVPA, at least in part by reducing
susceptibility to exercise-induced muscle damage.
Recent MR studies reported causal protective effects of
self-reported and objectively assessed physical activity on breast and
colorectal cancer62,63. One study concluded that a 1 s.d. increase in
self-reported MVPA was associated with lower odds of colorectal
cancer (OR = 0.56), with BMI only mediating 2% of the protective
effect63. Our results—on lung cancer rather than colorectal cancer—
show that instrumental variables of MVPA in multivariable MR are
weak, and results should be interpreted with caution. Furthermore,
a causal effect of objectively assessed, but not self-reported physical activity (MVPA) on depression has been reported64. Our MR
results for LST on depression show that although the physical activity trait matters, the self-reported nature of it seems inconsequential. According to an earlier study, TV viewing has an attenuated
effect but still causes coronary artery disease when adjusting for
BMI15. The discrepancy with our results—suggesting mediation
or confounding by BMI—highlights the importance of including
physical activity, as well as BMI-associated variants in multivariable MR analysis, to prevent loss of precision and potentially even
biased estimates31.
It is of interest that a proxy of rs429358, part of the established
APOE Ɛ4 risk allele for Alzheimer’s disease, is associated with
lower LST. Klimentidis et al. previously showed that the association of rs429358 with MVPA was stronger in those reporting a
family history of Alzheimer’s disease, and among older individuals13. Based on the direction of the association, it was hypothesized
that individuals at higher risk of developing Alzheimer’s disease
may adopt a healthy lifestyle to mitigate their risk, especially later
in life13. However, our MR analyses show no evidence of a causal
role of MVPA or LST in Alzheimer’s disease, and lower average
physical activity levels in individuals with a first-degree family history of Alzheimer’s disease or dementia13 suggest other explanations are more likely, although a role for survival bias cannot be
ruled out13. For example, APOE Ɛ4 carriers have a greater increase
in aerobic capacity following exercise training65, which may reinforce a physically active lifestyle independently of Alzheimer’s risk.
Furthermore, several studies have investigated the moderating role
of the APOE Ɛ4 allele in the relationship between physical activity
1338

and Alzheimer prevention66. Although more studies are needed to
resolve inconsistencies in the literature, Ɛ4 carriers seem to benefit
more from physical activity in terms of reducing the risk of dementia and brain pathology66.
To investigate the molecular basis for the association of ACTN3
with MVPA, we compare the ACTN3 p.Glu635 and p.635Ala variants (rs2229456) with each other and with ACTN2—as a functional proxy for ACTN3 p.577Ter—using MD simulations and
single fiber experiments. Previous studies using normal mode
analysis of alpha-actinin show that several of the natural frequencies have bending flexibility near residue 635. This is interesting because ACTN3’s residue 635—the 356th residue of the
spectrin repeat region (Fig. 6)—lies outside the linkers between the
α-helices of the spectrin repeats, where most flexibility is expected
and observed67. The absence of salt-bridge and hydrogen-bonding
interactions between position 635 (628 in ACTN2) and surrounding residues—due to either the presence of the alanine substitution
at ACTN3’s residue 635, or a kink in the α-helix at ACTN2’s residue 628—increases the flexibility of the dimer under a compressive load, with far less work required to deform the homodimer
beyond a compressive distance of 1.2 nm. The p.635Ala substitution may reduce the stiffness of the muscle fiber while undergoing
elastic deformation during exercise to a level that is comparable
with ACTN2. Although at the expense of the maximal force that
single fibers can generate, this may reduce exercise-induced microtrauma caused by Z-disc rupture or streaming1, alleviating delayed
onset muscle soreness2 and risk of injuries3, enabling a more active
lifestyle. Our results suggest it would be interesting to revisit the
plethora of data on p.Arg577Ter, and differentiate between effects
of the p.Arg577Ter and p.Glu635Ala variants.
In conclusion, our results shed light on genetic variants and
molecular mechanisms that influence physical activity and sedentary behavior in daily life. As would be expected for complex
behaviors that involve both motivation and physical ability, these
mechanisms occur in multiple organs and organ systems. In addition, our causal inference supports the important public health message that a physically active lifestyle mitigates the risk of multiple
diseases, in major part through or confounded by an effect on BMI.
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Fig. 6 | Allele p.635Ala in ACTN3 results in a more flexible ACTN3 homodimer. a, ACTN3 is a homodimer of two antiparallel filaments, with each filament
consisting of an N-terminal actin binding domain (ABD, blue), followed by a structural region comprised of four spectrin repeats (gray) with a C-terminal
calmodulin (CAM) homology domain (cyan). b, The glutamate residue side chain in position 635 of ACTN3 (p.Glu635) interacts primarily with the arginine in
position 638 and the glutamine in position 639. c, The α-helix comprised of residues adjacent to ACTN3 residue 635 (ACTN2 628) exhibits a pronounced kink
in ACTN2 (green) at this α-helical turn compared with ACTN3 p.Glu635 (blue) and p.635Ala (orange), decreasing the likelihood of interactions under load with
R631, whereas the alanine substitution of ACTN3 p.635Ala precludes any side chain interactions with neighboring residues p.Arg638 or p.Glu639. d, The r.m.s.f.
of the spectrin repeat structural region of the ACTN3 dimer for a 150 ns MD simulation for variants p.Glu635 (blue) and p.635Ala (orange, higher MVPA) and
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(red, positive and blue, negative). e, Umbrella sampling of ACTN3 variants p.Glu635 and p.635Ala and ACTN2 with orange, blue and green traces representing
the potential of mean force for ACTN3 variants p.635Ala (orange) and p.Glu635 (blue) and ACTN2 (green) ±1 s.d. The reaction coordinate is the distance
between the two ABD centers of mass of each dimer, a negative value indicating a shorter distance between the two ABDs. Inset shows the relaxed dimer at
reaction coordinate of 0 nm (top) and the direction and effect on the compressive force. f, Single fiber experiments show a higher maximal force and fiber power
during isotonic contractions after an eccentric exercise bout in type IIA fibers from an individual homozygous for p.Arg577 and p.Glu635 (blue) compared with
type IIA fibers from three p.Arg577 homozygous, p.Glu635Ala heterozygous individuals (orange); and from four p.577Ter homozygous individuals (green).
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Each study (Supplementary Table 2) obtained informed consent from participants
and approval from the appropriate institutional review boards or committees.
Samples and study design. We conducted a large meta-analysis for physical
activity traits, including results from up to 703,901 individuals (including nearly
half-a-million from the UK Biobank) to identify genetic loci associated with
physical activity and sedentary behavior across different ancestries. We first
examined genome-wide, ancestry- and sex-stratified associations in 51 studies
with questionnaire-based data on: (1) MVPA; (2) LST; (3) sedentary commuting
behavior; and/or (4) sedentary behavior at work, using study-specific, tailored
analysis plans (Supplementary Table 2, see Supplementary Note for rationale).
Next, we performed ancestry-specific, inverse variance-weighted fixed-effects
meta-analyses of summary statistics for each of the four self-reported traits
(Fig. 1a), including data from up to 703,901 individuals consisting of European
(94.0%), African (2.1%), East Asian (0.8%) and South Asian (1.3%) ancestries; as
well as Hispanics (1.9%) (Supplementary Table 1). Our primary meta-analyses were
restricted to 661,399 European ancestry participants. Secondary meta-analyses
were also conducted for: (1) all ancestries (European + other ancestries), (2)
European ancestry men, (3) European ancestry women, and (4) each non-European
ancestry separately. Details of participating studies are described in Supplementary
Tables 1 and 2. Although modest genomic inflation68 was observed (lambda
1.2–1.4) (Supplementary Fig. 1), LD score regression analyses indicated this reflects
true polygenic architecture rather than cryptic population structure69.
Self-reported physical activity and sedentary behavior traits. The self-reported
outcomes in this study are domain- and intensity-specific physical activity
and sedentary traits that, unlike accelerometry-based outcomes, are subject to
misclassification and bias by recall and awareness of the beneficial effects of
physical activity, among others. Furthermore, different studies used different
questionnaires to capture physical activity, and so we defined cohort-specific
traits that make optimal use of the available data, while striving for consistency
across studies (Supplementary Table 2). As a result, and based on the zero-inflated
negative binomial nature of the distribution of MVPA in most studies, we had
to analyze MVPA as a dichotomous outcome, which had a negative impact on
statistical power. Descriptive information of these four outcomes is reported by
study in Supplementary Table 1.
Genotyping, imputation and quality control. Detailed information about the
genotyping platform used, and quality control measures applied within each study
are presented in Supplementary Table 2. Quality control following study level
analyses was conducted using standard procedures70.
GWAS and meta-analyses. GWAS were performed within each study in a sexand ancestry-specific manner. Additive genetic models accounting for family
relatedness (where appropriate) were adjusted for age, age-squared, principal
components reflecting population structure and additional study-specific
covariates as presented in Supplementary Table 2. Analyses were limited
to genotyped and imputed variants with minor allele frequency >0.1% in
UK Biobank, and minor allele count >3 in other studies. Study-, sex- and
ancestry-specific GWAS results were meta-analyzed using the fixed-effects, inverse
variance-weighted method implemented in METAL71, for 19.1 to 22.5 million
SNPs per trait. Because we did not include a replication stage and given the high
SNP density, we applied a stricter than usual Bonferroni correction and considered
associations with P < 5 × 10−9 statistically significant72.
To identify genome-wide significant loci, we defined a distance criterion
of ±1 Mb surrounding each genome-wide significant peak (P < 5 × 10−9). We
extracted previously reported genome-wide significant associations within 1 Mb
of any index variants we identified from the NHGRI-EBI GWAS Catalog11 and
PhenoScanner V2 (ref. 73). A locus is considered previously reported if any variant
we extracted at that locus was in LD (r2 > 0.1) with a lead variant that has been
associated with objectively assessed or self-reported physical activity and sedentary
traits previously. To identify physical activity- and sedentary behavior-associated
loci that were previously associated with obesity-related traits, we performed a look
up for each lead variant (and their proxies with LD r2 > 0.2) in the GWAS catalog
and PhenoScanner V2.
SNP-based heritability estimation. To estimate the heritability explained
by genotyped SNPs for each physical activity and sedentary trait, we used
BOLT-REML variance components analysis74, a Monte Carlo average information
restricted maximum likelihood algorithm implemented in the BOLT-LMM v.2.3.3
software. As in most GWAS for complex traits, the SNP heritability (up to 16%)
was lower than the heritability estimates from twin studies (31%–71%)8,9, likely at
least in part due to the absence of rare variants in GWAS75.
Although we performed a multi-ancestry meta-analysis, data from relatively
few individuals of non-European ancestries were available to us, and our functional
follow-up analyses were conducted based on the European ancestry results. Studies
with data from more individuals of non-European ancestry will no doubt further
increase the understanding of physical activity etiology.
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Joint and conditional analyses. To identify additional independent signals in
associated loci, we performed approximate joint and conditional SNP association
analyses in each locus, using GCTA76. Any lead SNPs identified in known
long-range high-LD regions77 were treated as a single large locus in the GCTA
analysis. We used unrelated European ancestry participants from the UK Biobank
as the reference sample to acquire conditional P values for association.
MTAG. MTAG results were calculated using the European ancestry meta-analysis
results of LST and MVPA, using standard settings17. Because MTAG's estimates
are biased away from zero when SNPs are null for one trait but non-null for other
traits, we applied it to only the two outcomes that were most strongly genetically
correlated: MVPA and LST (absolute value of genetic correlation 0.49).
PheWAS with physical activity PGSs. To assess the out-of-sample predictive
power of the variants associated with self-reported sedentary behavior and physical
activity, we constructed two PGSs—for LST and for MVPA—in up to 23,723
Mount Sinai BioMe BioBank participants, using summary statistics of the primary
European ancestry meta-analyses and PRSice software78. We subsequently assessed
the association of MVPA and BMI with the PGSs in individuals of European
and African ancestry, as well as in Hispanic participants, within the BioMe
BioBank. Among the 2,765 European ancestry individuals with physical activity
measurements and genotypes, the PGSs were calculated on common variants
(minor allele frequency >1%) using P value thresholds from 5 × 10−8 to 1 (all
variants) in the LST and MVPA GWAS, and clumping parameters of r2 < 0.5 over a
250-kb window. Logistic regression models were used to examine the associations
between MVPA (defined as at least 30 min per week of MVPA yes/no in BioMe)
and the PGSs in European ancestry participants of BioMe. In each analysis, we
estimated the variance in MVPA explained by the PGS, adjusting for age, sex and
the top ten principal components for population structure. For both LST and
MVPA, the P value threshold resulting in the best performing PGS was defined
based on the highest R2 increase upon adding the PGS to the regression model. To
examine the generalizability of the two PGSs, we next examined their associations
with MVPA in 3,206 Hispanic individuals and 2,224 African ancestry participants
of BioMe. We then tested each PGS for classification performance and examined
whether the generated PGS was associated with any other trait by performing a
PheWAS. Briefly, International Classification of Diseases 9 and 10 codes from
electronic health records were mapped to phecodes using the PheWAS package79.
Among 8,959 BioMe European ancestry participants, the 1,039 disease outcomes
with at least ten cases were analyzed. We used logistic regression to separately
model each phecode as a function of the two PGSs, adjusting for age, age-squared,
sex and the top ten principal components. Interpretation of results was restricted
to outcomes with more than ten cases. Multiple testing thresholds for statistical
significance were set to P < 4.8 × 10−5 (0.05/1,039).
Genetic correlations. To explore a possibly shared genetic architecture, we next
estimated genetic correlations of the four self-reported traits examined in this study
and five accelerometry-assessed physical activity traits assessed in UK Biobank14
with relevant complex traits and diseases based on established associations at the
trait level using LD score regression implemented in the LD-Hub web resource18.
To define significance, we applied a Bonferroni correction for the 108 selected
phenotypes available on LD-Hub (P < 4.6 × 10−4). Supplementary Table 10 shows
the complete set of pairwise genetic correlations of the four self-reported physical
activity traits with relevant complex traits and diseases. Next, we prioritized traits
and diseases showing evidence of genetic overlap (associated with at least one
of the physical activity traits). These can be divided into six categories: lifestyle
traits, anthropometric traits, psychiatric diseases, other diseases (cardiometabolic
diseases and cancer), biomarkers and others (Fig. 4). Using objectively assessed
physical activity traits (accelerometry) instead of self-reported traits yielded similar
results (Supplementary Fig. 2).
Two-sample MR. We performed MR analyses to disentangle the causality between
LST and MVPA, on the one hand, and BMI, on the other hand. We further
investigated the causal effects of LST and MVPA on common diseases and risk
factors, while considering BMI through multivariable MR. For multivariable MR, we
used BMI (exposure 2) summary statistics based on UK Biobank data, and summary
statistics for disease outcomes and other relevant traits based on data from the
largest publicly available GWAS without data from UK Biobank participants on the
MR-Base platform and OpenGWAS database80,81. This way, we aimed to minimize
bias due to sample overlap in the two-sample MR analysis82. The source of each
of the instruments is presented in Supplementary Table 12. Genetic instrumental
variables for each of the traits and diseases consisted of genome-wide significant
(P < 5 × 10−8) index SNPs. Index SNPs were LD clumped (r2 > 0.001 within a 10-Mb
window) to remove any correlated variants. In the multivariable MR that evaluates
the independent effects of each risk factor, the genetic instrumental variables
from two risk factors were combined. For both LST and MVPA, independent loci
associated with physical activity or BMI were used as instrumental variables.
We followed several steps to evaluate potential causality. Because MR results
can be severely biased if instrumental SNPs show horizontal pleiotropy and violate
the instrumental variable assumptions28, we prioritized methods that are robust
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to horizontal pleiotropy when calculating causal estimates. We did not use the
MR-Egger intercept test to identify the presence of potential pleiotropy, because
the MR-Egger intercept parameter estimate is positively biased when the NO
Measurement Error assumption is violated, as indicated by lower values of I2GX in
our two-sample MR setting83. Instead, we applied MR-PRESSO (pleiotropy residual
sum and outlier)27, which removes pleiotropy by identifying and discarding
influential outlier predictors from the standard inverse variance-weighted test28.
For analyses with evidence of no distortion due to pleiotropy (MR-PRESSO
Global test P > 0.05), we considered other robust methods, for instance fixed- and
random-effect inverse variance-weighted, weighted- or simple- median and mode
methods. We also conducted Steiger filtering to remove variants likely influenced
by reverse causation and used Cook’s distance filtering to remove outlying
heterogeneous variants as deemed necessary. To select the most appropriate
approach, we implemented a machine learning framework30. Finally, we performed
a leave-one-out analysis to identify potential outliers among the variants included
in the instrumental variables tested. We set the multiple testing significance
threshold for MR analyses with disease outcomes at 1.9 × 10−3, that is, Bonferroni
correction for 13 disease outcomes and 2 types of risk factors: physical activity or
sedentary behavior and adiposity (0.05/(13 × 2)).
We also applied the recently published Bayesian-based MR method CAUSE,
which accounts for both correlated and uncorrelated pleiotropy26, in evaluating
bidirectional causal effects between physical activity and adiposity. Compared with
the other two-sample MR methods, CAUSE calculates the posterior probabilities
of the causal effect and the shared effect, and tests whether the causal model
fits the data better than the sharing model. That is, it examines whether the
association between the traits is more likely to be explained by causality than
horizontal pleiotropy. In addition, CAUSE improves the power of MR analysis by
using full genome-wide summary results (LD pruned at r2 < 0.1 with P < 1 × 10−3,
as recommended by the CAUSE authors). In addition, we took advantage of the
robustness of the CAUSE method—which allows overlapping GWAS samples—to
test the assumption that a genetic predisposition for LST assessed later in life
reflects a lifetime liability. Using the summary statistics of SNPs for childhood
adiposity (comparative body size at age 10) and height (comparative height at age
10) in UK Biobank84, we examined bidirectional causal effects between LST and
these two recalled childhood traits.
Enrichment for genes with altered expression in skeletal muscle after an
intervention. A high degree of physical fitness and a strong adaptive response to
exercise interventions facilitate a physically active lifestyle. To identify plausible
candidate genes in GWAS-identified loci, we examined enrichment for transcripts
whose expression in skeletal muscle was changed after an acute bout of aerobic
exercise, aerobic training, an acute bout of resistance exercise, resistance training
and inactivity33. We excluded individuals with pre-existing conditions such as
chronic kidney disease, chronic obstructive pulmonary disease, frailty, metabolic
syndromes and obesity. We also excluded athletes because in this subgroup,
transcripts with differential expression in response to (in)activity interventions are
likely not representative for the general population85. Enrichment was examined
for genes nearest to, or within 1 Mb of lead variants for LST- and MVPA-associated
loci. We used false discovery rate <0.01 as the threshold for altered expression after
intervention. A sensitivity analysis with a series of different false discovery rate
cut-offs (0.001 to 0.5) showed that results were robust.
Gene, tissue and cell-type prioritization. We used DEPICT40 to identify enriched
gene sets and tissues, as well as to prioritize candidate genes in the identified loci,
using variants with P < 1 × 10−5 in the primary meta-analysis of European ancestry
men and women combined as input. We also used CELLECT43 to identify enriched
cell types for physical activity, by combining MVPA and LST GWAS summary
statistics with single-cell RNA sequencing data. We sought to further refine the set
of prioritized candidate genes using SMR and HEIDI tests46. Briefly, this approach
integrates summary-level data from GWAS and expression quantitative trait loci
(eQTL) studies to test whether a transcript and phenotype are likely associated
because of a shared causal variant (pleiotropy). We considered genes candidates
if they had a Bonferroni-corrected PSMR < 1.02 × 10−5 and showed no evidence of
heterogeneity (PHEIDI > 0.05), as in earlier studies46. Based on tissue enrichment
results from DEPICT, the SMR analyses were performed using brain eQTL
information obtained from GTEx-brain (n = 72)86,87, CommonMind Consortium
(n = 467)88, ROSMAP (n = 494)89, and Brain-eMeta (n = 1,194)87; blood eQTL
summary information obtained from the eQTLGen Consortium90, which is based
on peripheral blood samples from 31,684 individuals; and skeletal muscle eQTL
information from the GTEx project (n = 803)91.
To identify variants in GWAS-identified loci with a high posterior
probability of being causal, we used LST and MVPA summary statistics as input
for FINEMAP47. We used default parameters and selected a maximum of ten
putative causal variants per locus. The output variants identified as credible were
mapped to genes using tissue-specific HiC chromatin conformation capture
data92. We integrated all HiC data in the brain (dorsolateral prefrontal cortex,
hippocampus, neural progenitor cell, and adult and fetal cortex) available
on FUMA v.1.3.5, using the same approach. Genes in GWAS-identified loci
containing FINEMAP-identified credible coding variants with a CADD score
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>12.33 were also prioritized. Finally, we used data from 26 of the 131 available
tissues and cell types deemed relevant for sedentary behavior and physical activity
(Supplementary Table 20) to identify genes that are contacted by enhancers
affected by causal variants flagged by GWAS lead SNPs, using the recently
described activity-by-contact model49.
Enrichment for previously reported candidate genes. We next conducted a
literature review of previously reported genes with evidence of a role in exercise
(physical activity behavior) and fitness (physical activity ability) and identified
58 such candidate genes (13 for exercise; 45 for fitness)12,50–53. For each gene, we
identified all variants within the gene, examined their associations with LST
and MVPA in our meta-analysis of European ancestry individuals and, for each
gene–trait combination, retained the summary statistics for the variant with the
lowest P value for association. Variants in three genes reached the traditional
threshold for genome-wide significance (PPARD, APOE and ACTN3). Based on
LD and predicted effects on protein function, rs2229456 in ACTN3 (encoding
p.Glu635Ala) may have a causal effect.
MD simulation for p.Glu635Ala. Because no structure for human ACTN3
has yet been experimentally determined, we constructed a homology model
of the p.Glu635 variant monomeric filament using the fully annotated protein
(UniProt ID Q08043) using Phyre2 (ref. 93), with the p.635Ala variant mutated in
silico. Residue 635 of ACTN3 resides in the 356th residue of the spectrin repeat
region and corresponds with residue 628 in ACTN2 (see the Supplementary
Methods for more information). For each variant, the spectrin repeats of the
ACTN3 monomer were aligned with the crystal structure of the rod domain of
alpha-actinin (PDB ID 1HCI), to give the dimeric form of ACTN3. MD system
preparation and simulation was conducted with GROMACS 2020.1 (ref. 94) and
using mdanalysis v.2.0. The MD topology was created with GROMACS pdb2gmx
using the ACTN2 and ACTN3 dimer models and parameterized with the
CHARMM36 all-atom force field95. The ACTN2 and ACTN3 dimers were placed
in a rectangular simulation box with a 1.0-nm buffer between the protein and
the box extent, with periodic boundary conditions in all three spatial axes. The
system was solvated with TIP3P water molecules and using GROMACS genion,
random solvent molecules were replaced with K+ and Cl− to a concentration of
150 mM with additional K+ ions added to provide an electrostatically neutral
system. Energy minimization was accomplished using the steepest descent
algorithm. To equilibrate the system, two 100-ps simulations were conducted
using a constant temperature ensemble (NVT, that is, a constant number
of particles [N], volume [V] and temperature [T]) at 310 K via a Berendsen
thermostat, followed by a constant pressure ensemble (NPT, that is, a constant
number of particles [N], pressure [P] and temperature [T]) at 1 bar with a
Parinello–Rahman barostat. MD simulation parameters were set in accordance
with the recommendations for the CHARMM36 force field in GROMACS. A
short production run of 1 ns without position restraints was followed by a full
simulation of 150 ns with weak position restraints on the ABD of chain B to
prevent self-interaction across the periodic boundaries.
Steered MD and umbrella sampling for p.Glu635Ala. We next compared the
properties of ACTN2 and of ACTN3 p.635Ala and p.Glu635 when placed under
the simulated compressive loads that are likely experienced in vivo. The final frame
of the 1-ns MD production run was used as the starting topology for steered MD
simulations using fully relaxed dimers. Steered MD simulations were run for 2 ns
with a pulling rate of 0.005 nm ps−1 and a harmonic potential of 50 kJ mol−1 nm−2.
Center-of-mass pull groups were defined as the ABD of each respective monomer,
with a weak position restraint placed on the Cα atom of threonine 52 (ACTN3) or
threonine 45 (ACTN2)—a centrally located residue in the core of the ABD—on
one ABD, enabling full rotational freedom of each ABD during the course of the
steered MD simulations. The pulling vector was oriented along the axis on which
the spectrin repeats were initially aligned. Suitable frames from each steered MD
simulation were selected that differed by no more than 0.2 nm from 0 to −5.5 nm
(a contraction of the dimer by 5.5 nm or ~18%) and were used as the starting
topology for a series of 10-ns umbrella sampling simulations. Analysis of the
umbrella sampling simulations was conducted using g_wham, to yield the potential
of mean force versus reaction coordinate for each variant.
Single skeletal muscle fiber functional characteristics in relation to
p.Glu635Ala. Single muscle fibers from eight nonathletic young men in which
contractile and morphological properties were previously characterized in
vastus lateralis biopsies obtained before and after an eccentric exercise bout60,61
were genotyped for rs2229456. A hierarchical linear mixed effects model was
constructed for each fiber type and time point using rstanarm96 to test the genotype
fixed effect, with muscle fibers nested within each of the eight individuals as
random factors for each contractile and morphological variable. Genotypes at
p.Arg577Ter and p.Glu635Ala were clustered into three groups: RR-AA (n = 1
individual, 46 fibers, reference group); RR-AC (n = 3 individuals, 32 ± 5 fibers);
and XX-AA (n = 4 individuals, 39 ± 6 fibers). Using weakly informative priors, the
posterior distribution was estimated with Markov chain Monte Carlo sampling
(20,000 samples total with 5,000 sample burn-in). We calculated 90% credible
Nature Genetics | www.nature.com/naturegenetics
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We made use of publicly available software and tools such as METAL (https://
genome.sph.umich.edu/wiki/METAL), GCTA (https://yanglab.westlake.edu.cn/
software/gcta/), LD score regression (https://github.com/bulik/ldsc), SMR (https://
cnsgenomics.com/software/smr/) and PLINK (www.cog-genomics.org/plink/).
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Extended Data Fig. 1 | LST-associated loci are enriched for genes with altered expression in skeletal muscle following resistance training. Fold-change
plot in log scale for the ratio between: (1) the proportion of genes in physical activity-associated loci that showed an altered expression in skeletal muscle
(FDR < 0.01) across five categories: inactivity, acute bout of resistance exercise, acute bout of aerobic exercise, resistance training, or aerobic training;
and (2) the proportion of all genes that showed an altered expression following such (in)activity in the MetaMex database (PMID: 31980607). Tested loci
were MVPA or LST-associated loci. In a given set of loci, we either considered only the genes nearest to the lead SNP, or all genes within 1 Mb of the lead
SNP. Only loci harboring at least five genes with altered gene expression levels after intervention were included in this figure. A one-sided Fisher exact test
was used to calculate the P-value for enrichment.
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Extended Data Fig. 2 | A sensitivity analysis shows the analysis of altered gene expression following resistance training is robust to FDR threshold. We
examined the effect of different FDR thresholds on Fisher’s exact test results for the enrichment analysis of alteration in gene expression in skeletal muscle
following resistance training. Red square, genes within 1 Mb of the LST lead SNP; green circle, genes within 1 Mb of the MVPA lead SNP; blue triangle,
nearest gene LST lead SNP; purple diamond, nearest gene MVPA lead SNP. The horizonal dotted line indicates nominal significance level (P < 0.05), and
the vertical dashed line indicates the FDR threshold that was used. FDR thresholds explored range from 0.001 to 0.5.
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Extended Data Fig. 3 | DEPICT-derived tissue enrichment of MVPA and LST. a, MVPA. b, LST. SNPs with P < 1 x 10−5 for association in the European
ancestry GWAS of men and women combined were used as input. The dashed line indicates the FDR corrected significance threshold (FDR < 0.05).
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Extended Data Fig. 4 | Cell type prioritization using CELLECT for MVPA and LST. a, Prioritization of 115 Tabula Muris cell types across 19 tissues identified
two cell types from the brain as significantly associated (stratified linkage disequilibrium score regression) with MVPA (left) and LST (right), namely
oligodendrocyte precursor cells and neurons (shown in black; Bonferroni-corrected significance threshold, P < 0.05/115). b, Prioritization of 265 mouse
nervous system cell types identified 13 and 45 cell types from 12 distinct brain regions as significantly associated (stratified linkage disequilibrium score
regression) with MVPA and LST, respectively (highlighted; Bonferroni-corrected significance threshold, P < 0.05/265.

Nature Genetics | www.nature.com/naturegenetics

NATurE GEnETICS

Articles

Extended Data Fig. 5 | Protein-protein interactions involving 17 of the 46 candidate genes in GWAS-identified loci prioritized by at least two
approaches. Protein-protein interactions were visualized using String. LONRF2 and CHST10 were prioritized in loci associated with MVPA; the remaining
genes were prioritized in loci associated with LST.
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